Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials.

CONCLUSIONS: Dupilumab alone or with TCS improved signs and symptoms of AD, had an acceptable safety profile, and suppressed biomarkers of type 2 inflammation compared to placebo in Japanese adult patients with moderate-to-severe AD.
PMID: 31564057 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - September 27, 2019 Category: Dermatology Authors: Katoh N, Kataoka Y, Saeki H, Hide M, Kabashima K, Etoh T, Igarashi A, Imafuku S, Kawashima M, Ohtsuki M, Fujita H, Arima K, Takagi H, Chen Z, Shumel B, Ardeleanu M Tags: Br J Dermatol Source Type: research